199 related articles for article (PubMed ID: 17201266)
1. [Tadalafil and patients preference in the treatment of erectile dysfunction].
Hu JL; Chen B
Zhonghua Nan Ke Xue; 2006 Dec; 12(12):1145-8. PubMed ID: 17201266
[TBL] [Abstract][Full Text] [Related]
2. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
Lee J; Pommerville P; Brock G; Gagnon R; Mehta P; Krisdaphongs M; Chan M; Chan J; Dickson R
BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
4. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.
Brock G; Chan J; Carrier S; Chan M; Salgado L; Klein AH; Lang C; Horner R; Gutkin S; Dickson R
BJU Int; 2007 Feb; 99(2):376-82. PubMed ID: 17155989
[TBL] [Abstract][Full Text] [Related]
5. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
6. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
7. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
8. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
Mirone V; Fusco F; Rossi A; Sicuteri R; Montorsi F
BJU Int; 2009 May; 103(9):1212-7. PubMed ID: 19154480
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
[TBL] [Abstract][Full Text] [Related]
10. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
Ahn TY; Lee SW; Kim SW; Yang DY; Park NC; Min KS; Park K; Paick JS; Dyachkova Y; Dwight T; Lee MS
Asian J Androl; 2007 Nov; 9(6):760-70. PubMed ID: 17968461
[TBL] [Abstract][Full Text] [Related]
11. [ED patients and their female partners prefer tadalafil].
Gong BS
Zhonghua Nan Ke Xue; 2011 Jun; 17(6):571-5. PubMed ID: 21735661
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of tadalafil for erectile dysfunction: an updated review].
Rui WB; Chen XW
Zhonghua Nan Ke Xue; 2009 Oct; 15(10):956-9. PubMed ID: 20112748
[TBL] [Abstract][Full Text] [Related]
13. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
15. [Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours].
Deng SM
Zhonghua Nan Ke Xue; 2008 Sep; 14(9):857-60. PubMed ID: 18998474
[TBL] [Abstract][Full Text] [Related]
16. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
17. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
18. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
19. [Benefits of tadalafil in sexual activity-related time concerns].
Yuang RQ
Zhonghua Nan Ke Xue; 2010 Jun; 16(6):572-5. PubMed ID: 20608366
[TBL] [Abstract][Full Text] [Related]
20. [Tadalafil for erectile dysfunction: excellent safety and tolerance].
Bai WJ
Zhonghua Nan Ke Xue; 2009 Jan; 15(1):92-5. PubMed ID: 19288756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
